Relevant bibliographies by topics / Trigla lyra / Journal articles
To see the other types of publications on this topic, follow the link: Trigla lyra.

Journal articles on the topic 'Trigla lyra'

Author: Grafiati
Published: 10 September 2021
Last updated: 29 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Trigla lyra.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Magi, G. E., M. Iannaccone, C. Gili, and G. Rossi. "Cardiac cholesterol granulomas in a piper gurnard,Trigla lyra(L.)." Journal of Fish Diseases 32, no. 5 (2009): 473–75. http://dx.doi.org/10.1111/j.1365-2761.2009.01031.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Caragitsou, E., and C. Papaconstantinou. "Feeding habits of piper (Trigla lyra) in the Saronikos Gulf (Greece)." Journal of Applied Ichthyology 10, no. 2-3 (1994): 104–13. http://dx.doi.org/10.1111/j.1439-0426.1994.tb00149.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Silva, Frederica, Ana M. Duarte, Susana Mendes, et al. "Seasonal Sensory Evaluation of Low Commercial Value or Unexploited Fish Species from the Portuguese Coast." Foods 9, no. 12 (2020): 1880. http://dx.doi.org/10.3390/foods9121880.

Full text
Abstract:
Overfishing is increasing over time, and according to FAO (Food and Agriculture Organization), about one third of the world’s fish stocks are now overfished. Thus, diversifying the target species is essential for fisheries sustainability contributing to improve resource-efficient processes. Non-target species can be valuable resources for the development of new food products. However, those species are scarcely studied, and it is of high importance to trace their seasonal sensory profile as a first step towards their valorisation. Therefore, in this study, seasonal influence on sensory propert
APA, Harvard, Vancouver, ISO, and other styles
4

Loukas, Vassilis, Christos Dimizas, Vassilia J. Sinanoglou, and Sofia Miniadis-Meimaroglou. "EPA, DHA, cholesterol and phospholipid content in Pagrus pagrus (cultured and wild), Trachinus draco and Trigla lyra from Mediterranean Sea." Chemistry and Physics of Lipids 163, no. 3 (2010): 292–99. http://dx.doi.org/10.1016/j.chemphyslip.2010.01.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Silva, Frederica, Ana M. Duarte, Susana Mendes, et al. "Adding Value to Bycatch Fish Species Captured in the Portuguese Coast—Development of New Food Products." Foods 10, no. 1 (2020): 68. http://dx.doi.org/10.3390/foods10010068.

Full text
Abstract:
We live in a world of limited biological resources and ecosystems, which are essential to feed people. Consequently, diversifying target species and considering full exploitation are essential for fishery sustainability. The present study focuses on the valorization of three low commercial value fish species (blue jack mackerel, Trachurus picturatus; black seabream, Spondyliosoma cantharus; and piper gurnard, Trigla lyra) and of two unexploited species (comber, Serranus cabrilla and boarfish, Capros aper) through the development of marine-based food products with added value. A preliminary inq
APA, Harvard, Vancouver, ISO, and other styles
6

Adão, Ana C., Michael Breen, Moritz Eichert, and Teresa C. Borges. "By-catch species susceptibilities and potential for survival in Algarve (southern Portugal) deep-water crustacean trawl fishery." Scientia Marina 82, S1 (2018): 141. http://dx.doi.org/10.3989/scimar.04740.02a.

Full text
Abstract:
Bottom trawling for crustaceans in Portuguese coastal waters is an important fishery in terms of revenue, despite its negative impacts on deep-sea ecosystems. This fishery catches large amounts of unwanted species that were discarded for various reasons before the introduction of the Landing Obligation, which banned the discarding of regulated species. However, where it can be demonstrated that a species has an acceptably high likelihood of survival, exemptions to this ban may be granted. In this study, time-to-mortality was used to estimate immediate mortality rates and identify important bio
APA, Harvard, Vancouver, ISO, and other styles
7

Sarkozy, Clementine, Mary Callanan, Catherine Thieblemont, et al. "Obinutuzumab Versus Rituximab in Transplant Eligible Untreated MCL Patients, a Matching Comparison between the Lyma and Lyma-101 Trials." Blood 142, Supplement 1 (2023): 980. http://dx.doi.org/10.1182/blood-2023-174416.

Full text
Abstract:
Aim: Obinutuzumab (O) and Rituximab (R) have never been compared in a prospective randomized trial in mantle cell lymphoma (MCL). The LYMA-101 trial (NCT02896582) investigated the Obinutuzumab-DHAP (O-DHAP) regimen followed by autologous stem cell transplant (O-BEAM, ASCT) plus O maintenance (OM) in transplant eligible patients <66y with untreated MCL (Le Gouill et al, Lancet Hem 2020). The LYMA trial (NCT00921414) used the same regimen with Rituximab instead of Obinutuzumab (Le Gouill et al, NEJM 2017). Herein, we report the long-term outcome of patients enrolled in the LYMA-101 trial
APA, Harvard, Vancouver, ISO, and other styles
8

Maurer, Matthew J., Hervé Ghesquières, Brian K. Link, et al. "Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials." Journal of Clinical Oncology 36, no. 16 (2018): 1603–10. http://dx.doi.org/10.1200/jco.2017.76.5198.

Full text
Abstract:
Purpose Selection bias in clinical trials has consequences for scientific validity and applicability of study results to the general population. There is concern that patients with clinically aggressive disease may not have enrolled in recent diffuse large B-cell lymphoma (DLBCL) trials due to the consent process and the inability to delay therapy for eligibility evaluation. We have examined the diagnosis-to-treatment interval (DTI) and its association with clinical factors and outcome in a clinic-based observational cohort of patients with DLBCL from the United States. Validation of results w
APA, Harvard, Vancouver, ISO, and other styles
9

Kelly, Jennifer L., Gilles Salles, Bryan Goldman, et al. "Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies." Journal of Clinical Oncology 33, no. 13 (2015): 1482–90. http://dx.doi.org/10.1200/jco.2014.57.5092.

Full text
Abstract:
Purpose Recent literature reports a potential association between high vitamin D and improved lymphoma prognosis. We evaluated the impact of pretreatment vitamin D on follicular lymphoma (FL) outcome. Patients and Methods SWOG participants were previously untreated patients with FL enrolled onto SWOG clinical trials (S9800, S9911, or S0016) involving CHOP chemotherapy plus an anti-CD20 antibody (rituximab or iodine-131 tositumomab) between 1998 and 2008. Participants included in our second independent cohort were also previously untreated patients with FL enrolled onto the Lymphoma Study Assoc
APA, Harvard, Vancouver, ISO, and other styles
10

Bodet-Milin, Caroline, Clement Bailly, Michel Meignan, et al. "Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group." Blood 126, no. 23 (2015): 335. http://dx.doi.org/10.1182/blood.v126.23.335.335.

Full text
Abstract:
Abstract INTRODUCTION. FGD-PET has emerged as an important predictor of clinical outcome in lymphomas. However, its utility in everyday clinical practice in mantle cell lymphoma (MCL) remains uncertain because there is a lack of large prospective trials including FDG-PET results. To address this question, we conducted the LyMa-MRD project as an ancillary study in a prospective phase III trial in MCL (NCI NCT00921414; LyMa Trial). From Sept 2008 to Aug 2012, 299 previously untreated MCL patients (<66yrs) were enrolled in the LyMa trial (a phase III international prospective trial, NCT009
APA, Harvard, Vancouver, ISO, and other styles
11

Maraldo, Maja V., Francesco Giusti, Ivan R. Vogelius, et al. "Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials." Lancet Haematology 2, no. 11 (2015): e492-e502. http://dx.doi.org/10.1016/s2352-3026(15)00153-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Callanan, Mary B., Caroline Milin, Marie-Helene Delfau-Larue, et al. "Predictive Power of Early, Sequential Minimal Residual Disease and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Monitoring in Young Patients with Mantle Cell Lymphoma in the Lyma Trial: A Lysa Study." Blood 144, Supplement 1 (2024): 1596. https://doi.org/10.1182/blood-2024-208081.

Full text
Abstract:
PURPOSE Minimal residual disease (MRD) can predict outcomes in patients with mantle cell lymphoma (MCL) but data are limited for younger patients undergoing ASCT (autologous-stem-cell-transplantation) and rituximab maintenance (RM) and no data are available on the clinical value of combining MRD with positron-emission-tomography (PET). PATIENTS AND METHODS. Long term follow-up data from a phase III trial in newly-diagnosed MCL patients of < 66 years (LYMA; NCI NCT00921414, Sarkozy C et al, J Clin Oncol, 2023) were examined to determine the relationship between MRD, PET and progression-f
APA, Harvard, Vancouver, ISO, and other styles
13

Le Gouill, Steven, Mary Callanan, Elizabeth Macintyre, et al. "Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study." Blood 120, no. 21 (2012): 152. http://dx.doi.org/10.1182/blood.v120.21.152.152.

Full text
Abstract:
Abstract Abstract 152 Mantle cell lymphoma (MCL) is a rare B-cell malignancy characterized by the t(11;14) translocation. The European MCL network has demonstrated that a sequential R-CHOP/R-DHAP chemotherapy regimen prior to autologous stem cell transplantation (ASCT) provides better disease control than R-CHOP (Hermine et al, ASH 2010, abstract 110) and that molecular minimal residual disease (MRD) measured by IGH real-time quantitative polymerase chain reaction (PCR) before and after ASCT is an important prognostic factor to predict progression-free survival (PFS) (Pott et al. Blood. 2010;1
APA, Harvard, Vancouver, ISO, and other styles
14

Burroni, Barbara, Anne Moreau, Mathieu Baldacini, et al. "P16, c-Myc, SOX11, P53, ki67 and CD71Protein Expression in Aggressive Morphological Variants of Mantle Cell Lymphomas Compared to Classical Morphological Mantle Cell Lymphomas in Multiple Clinical Trials." Blood 134, Supplement_1 (2019): 2820. http://dx.doi.org/10.1182/blood-2019-129790.

Full text
Abstract:
On behalf of the Lymphoma Study Association (LYSA) Introduction: Aggressive Mantle Cell Lymphoma variant (A-MCL), including blastic and pleomorphic morphological variants, is a rare subtype of MCL whose frequency varies around 10-15% of all newly-diagnosed MCL patients. According to 2017 World Health Organization (WHO) classification, the diagnosis of A-MCL is based on morphology. A high proliferation rate on Ki-67 staining is not sufficient to be classified as a blastoid or pleomorphic subtype. This might induce diagnostic confusion. The aim of the present retrospective study is to investigat
APA, Harvard, Vancouver, ISO, and other styles
15

Baldacini, M., B. Burroni, S. Le Gouill, et al. "CLINICO-BIOLOGICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR AGRESSIVE MANTLE CELL LYMPHOMA PATIENTS INCLUDED IN CLINICAL TRIALS. A LYSA STUDY." Hematological Oncology 37 (June 2019): 237–38. http://dx.doi.org/10.1002/hon.48_2630.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

F Rowe, Michael. "Effect of Shell Cover Color on Solar Absorptance and Environmental Heating of Cricket Helmets: A Pilot Study." Journal of Mineral and Material Science (JMMS) 5, no. 3 (2024): 1–6. http://dx.doi.org/10.54026/jmms/1090.

Full text
Abstract:
The objective of this pilot study was to quantify and describe the effect of shell cover color on solar absorptance, a1 (%; mean ± SD) and the temperature of the cricket helmet shell covers, Thsc (°C; mean ± SD) during exposure to a hot outdoor environment (WBGT 32.5 ± 1.9 °C; ACSM Heat Index Black; Extreme Danger STOP). We measured and recorded a1 in yellow, red and black cricket helmets using a micro-solarimeter. Thermographic imaging was used to quantify differential Thsc . Variations in shell cover color had a statistically significant (p<0.0002) 2-fold effect on a1 . At the end of 30-m
APA, Harvard, Vancouver, ISO, and other styles
17

Le Gouill, Steven, Catherine Thieblemont, Emmanuel Gyan, et al. "High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial." Blood 116, no. 21 (2010): 1758. http://dx.doi.org/10.1182/blood.v116.21.1758.1758.

Full text
Abstract:
Abstract Abstract 1758 Background: The LyMa trial is established as a randomized, open-label, phase III study, to evaluate the efficacy of rituximab maintenance after autologous stem-cell transplantation (ASCT) in untreated mantle cell lymphoma (MCL) patients aged between 18 and 65 years old. The LyMa trial opened in September 2008. As of July 2010, 114 patients have been included. As in many other lymphoma entities, R-CHOP is still considered a standard of care for upfront MCL patients before ASCT. However, only 30–40% of MCL patients reach CR/CRu after R-CHOP. Since the response status (CR v
APA, Harvard, Vancouver, ISO, and other styles
18

Baldacini, M., B. Burroni, S. Le Gouill, et al. "PS1251 CLINICO-BIOLOGICAL CHARACTERISTICS AND TREATMENT OUTCOMES FOR BLASTOID MANTLE CELL LYMPHOMA PATIENTS INCLUDED IN CLINICAL TRIALS. A LYSA STUDY." HemaSphere 3, S1 (2019): 571. http://dx.doi.org/10.1097/01.hs9.0000563284.81673.8e.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Gambari, Roberto, Aliyu Dahiru Waziri, Hemali Goonasekera та Emmanuel Peprah. "Pharmacogenomics of Drugs Used in β-Thalassemia and Sickle-Cell Disease: From Basic Research to Clinical Applications". International Journal of Molecular Sciences 25, № 8 (2024): 4263. http://dx.doi.org/10.3390/ijms25084263.

Full text
Abstract:
In this short review we have presented and discussed studies on pharmacogenomics (also termed pharmacogenetics) of the drugs employed in the treatment of β-thalassemia or Sickle-cell disease (SCD). This field of investigation is relevant, since it is expected to help clinicians select the appropriate drug and the correct dosage for each patient. We first discussed the search for DNA polymorphisms associated with a high expression of γ-globin genes and identified this using GWAS studies and CRISPR-based gene editing approaches. We then presented validated DNA polymorphisms associated with a hig
APA, Harvard, Vancouver, ISO, and other styles
20

Callanan, Mary B., Marie-Hélène Delfau, Elizabeth Macintyre, et al. "Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Interim Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group." Blood 126, no. 23 (2015): 338. http://dx.doi.org/10.1182/blood.v126.23.338.338.

Full text
Abstract:
Abstract INTRODUCTION : Minimal residual disease (MRD) is emerging as an important predictor of clinical outcome in patients with mantle cell lymphoma (MCL). However, its utility in everyday clinical practice remains uncertain since standardized MRD monitoring strategies and response criteria are not yet formally established. To address this question, we conducted the LyMa-MRD project as an ancillary biology study in a prospective phase III trial in MCL (NCI NCT00921414; LyMa Trial). METHODS : The present MRD analysis was performed in a subgroup of randomized patients (n=178) of the 299 MCL pa
APA, Harvard, Vancouver, ISO, and other styles
21

Augustin, Alix, Steven Le Gouill, Rémy Gressin, et al. "Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries." Journal of Cancer Research and Clinical Oncology 144, no. 4 (2017): 629–35. http://dx.doi.org/10.1007/s00432-017-2529-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Lytvynova, Olga, Jenna Jwayyed, Maha Hameed, et al. "Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients; A Scoping Review." Blood 142, Supplement 1 (2023): 6590. http://dx.doi.org/10.1182/blood-2023-190335.

Full text
Abstract:
Introduction Multiple myeloma is a hematological malignancy characterized by the uncontrolled proliferation of plasma cells within the bone marrow, with an increasing incidence and mortality in the last decade. Eligibility for stem cell transplantation plays a crucial role in determining the approach to treatment, with transplant eligible patients undergoing triple induction therapy with an immunomodulatory agent, a proteasome inhibitor, and steroid. We aimed to review the recent data on the available treatment options for newly diagnosed multiple myeloma (NDMM) in transplant eligible patients
APA, Harvard, Vancouver, ISO, and other styles
23

Dubois, Sydney, Bruno Tesson, Pierre-Julien Viailly, et al. "Integrative Analysis of Diffuse Large B Cell Lymphoma Mutational Landscape: A Lysa Study." Blood 126, no. 23 (2015): 1472. http://dx.doi.org/10.1182/blood.v126.23.1472.1472.

Full text
Abstract:
Abstract Introduction Diffuse Large B Cell Lymphoma (DLBCL) is the most common lymphoid malignancy, accounting for 30-40% of all Non Hodgkin Lymphomas. Gene expression profiling (GEP) has identified three main subtypes of DLBCL: Germinal Center B-cell like (GCB), Activated B-Cell like (ABC) and Primary Mediastinal B-cell Lymphoma (PMBL). Recently, Next Generation Sequencing (NGS) has enabled a more detailed characterization of DLBCL mutational profiles. Conventional techniques such as immunohistochemistry (IHC) and FISH are also widely used to describe DLBCL. However, no study has yet performe
APA, Harvard, Vancouver, ISO, and other styles
24

Sarkozy, Clémentine, Nicolas Mounier, Alain Delmer, et al. "Impact of BMI and Gender on Outcomes in DLBCL Patients Treated with R-CHOP: A Pooled Study from the LYSA." Lymphoma 2014 (January 16, 2014): 1–12. http://dx.doi.org/10.1155/2014/205215.

Full text
Abstract:
In diffuse large B-cell lymphoma (DLBCL), the age-adjusted International Prognostic Index (aaIPI) score is currently used to predict patient outcomes and to choose the best therapeutic treatment. Body mass index (BMI) and gender are occasionally sited as prognostic factors; however, their value has never been studied in a large series of patients included in prospective clinical trials in the rituximab era. To assess the impact of BMI and gender on OS and PFS independently of the aaIPI score, we pooled 985 patients that were prospectively included in GELA studies and uniformly treated with R-C
APA, Harvard, Vancouver, ISO, and other styles
25

Ziepert, Marita, Bettina Altmann, Viola Poeschel, et al. "A Simplified IPI Including BCL2 Identifies IPI 3 Patients with Poor Prognosis - a GLA/ Dshnhl and Lysa Collaboration." Blood 142, Supplement 1 (2023): 191. http://dx.doi.org/10.1182/blood-2023-184611.

Full text
Abstract:
Introduction: The original IPI remains valid to identify prognostic groups of DLBCL patients (pts) treated with R-CHOP (Ruppert et al. Blood 2020) and has been used to define eligibility for more than 20 studies randomizing pts between R-CHOP and R-CHOP + X, none of which except the Polarix study met its endpoint. One reason why some studies failed was the inclusion of IPI 2/3 pts equalizing the difference between standard and experimental arm although significant survival differences in pts with higher IPI were detected. Following the WHO-HAEM5 classification, determination of BCL2 and MYC re
APA, Harvard, Vancouver, ISO, and other styles
26

Sutcliffe, Catherine G., Lindsay R. Grant, Emily Cloessner, et al. "Association of Laboratory Methods, Colonization Density, and Age With Detection of Streptococcus pneumoniae in the Nasopharynx." American Journal of Epidemiology 188, no. 12 (2019): 2110–19. http://dx.doi.org/10.1093/aje/kwz191.

Full text
Abstract:
Abstract Culture-based methods for detecting Streptococcus pneumoniae in the nasopharynx lack sensitivity. In this study, we aimed to compare the performance of culture and molecular methods in detecting pneumococcus in the nasopharynx of healthy individuals and to evaluate the associations of age and colonization density with detection. Between 2010 and 2012, nasopharyngeal specimens were collected from healthy individuals living on Navajo Nation and White Mountain Apache Tribal lands in the United States. Pneumococci were detected by means of broth-enrichment culture and autolysin-encoding g
APA, Harvard, Vancouver, ISO, and other styles
27

Jardin, Fabrice, Anais Pujals, Laura Pelletier, et al. "Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study." Blood 126, no. 23 (2015): 129. http://dx.doi.org/10.1182/blood.v126.23.129.129.

Full text
Abstract:
Abstract Background and aim of the study Primary mediastinal B-cell lymphoma (PMBL) is an entity of aggressive B-cell lymphoma that is clinically and biologically distinct from the other molecular subtypes of diffuse large B-cell lymphoma (DLBCL). We recently detected by Whole exome sequencing a recurrent point mutation in the XPO1 (exportin 1) gene (also referred to as chromosome region maintenance 1; CRM1), which resulted in the Glu571Lys (p.E571K) missense substitution in 2 refractory/relapsed PMBL (Dubois et al., ICML 2015; Mareschal et al. AACR 2015). XPO1 is a member of the Karyopherin-b
APA, Harvard, Vancouver, ISO, and other styles
28

Goungounga, Juste Aristide, and Roch Giorgi. "Commentary on: Survival benefit of mantle cell lymphoma patients enrolled in clinical trials; a joint study from the LYSA group and French cancer registries." Journal of Cancer Research and Clinical Oncology 144, no. 4 (2018): 791–93. http://dx.doi.org/10.1007/s00432-017-2559-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Frontzek, Fabian, Loïc Renaud, Ulrich Duehrsen, et al. "Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration." Blood 142, Supplement 1 (2023): 71. http://dx.doi.org/10.1182/blood-2023-178815.

Full text
Abstract:
Introduction: Depending on clinical and molecular risk factors, CNS relapse occurs in 1-15% of DLBCL patients (pts) and is associated with dismal outcomes. Despite its important role in further improving DLBCL therapy, a comprehensive and large-scale characterization of secondary CNS relapse remains challenging. Methods: We conducteda retrospective analysis of 7775 pts treated within 19 prospective German and French phase 2/3 trials to identify and characterize DLBCL pts with progression or relapse in the CNS. Pts with histology different from DLBCL (subtypes), not treated with anti-CD20 antib
APA, Harvard, Vancouver, ISO, and other styles
30

Mounier, Nicolas, Sabine Anthony, Raphael Busson, et al. "Long term toxicity and fatigue after treatment for non-Hodgkin lymphoma (NHL): An analysis of twelve collaborative lymphoma study association (LYSA) trials, the Simonal Study." Journal of Clinical Oncology 34, no. 15_suppl (2016): 7518. http://dx.doi.org/10.1200/jco.2016.34.15_suppl.7518.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Rossi, Cédric, Marc André, Clémentine Joubert, et al. "Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response." Blood 134, Supplement_1 (2019): 128. http://dx.doi.org/10.1182/blood-2019-125976.

Full text
Abstract:
Introduction High risk stage IIB Hodgkin lymphoma (HL) with mediastinum-to-thorax ratio of ≥0.33 or extranodal localization are defined as a poor prognosis subset according to German Hodgkin study group (Sieber et al., Ann. of Oncol. 2000). These patients were treated consecutively in our group as limited stage in the EORTC/LYSA/FIL H10 study (André et al, JCO 2017) or advanced stage in the AHL2011 LYSA trial (Casasnovas et al., Lancet Oncol 2019). However, the relative efficacy of each of these strategies to control disease is unknown in this uncommon subset of patients. In the present retros
APA, Harvard, Vancouver, ISO, and other styles
32

Sibon, David, Christian Gisselbrecht, Thierry Jo Molina, et al. "Outcome of Patients with Primary Mediastinal Large B-Cell Lymphoma after R-CHOP21, R-CHOP14 and R-ACVBP: A Pooled Analysis of Clinical Trials from Lysa." Blood 140, Supplement 1 (2022): 1082–84. http://dx.doi.org/10.1182/blood-2022-166228.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Cottereau, A., A. Versari, J. Dupuis, et al. "PROGNOSTIC MODEL FOR HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA INCLUDING BASELINE TOTAL METABOLIC TUMOR VOLUME AND END INDUCTION PET: a POOLED ANALYSIS FROM LYSA AND FIL TRIALS." Hematological Oncology 35 (June 2017): 116–17. http://dx.doi.org/10.1002/hon.2437_105.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Chaillol, I., V. Letailleur, F. Cherblanc, et al. "P40 - External control arm from mixed clinical trials and real-world data from LYSA group for untreated diffuse large B cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials." Journal of Epidemiology and Population Health 73 (May 2025): 203071. https://doi.org/10.1016/j.jeph.2025.203071.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Letailleur, Valentin, Isabelle Chaillol, Fanny Cherblanc, et al. "Synthetic Control Arm from Clinical Trials and Real-World Data from Lysa Group for Untreated Diffuse Large B Cell Lymphoma Patients Aged over 80 Years: A Bona Fide Strategy for Innovative Clinical Trials." Blood 142, Supplement 1 (2023): 72. http://dx.doi.org/10.1182/blood-2023-177708.

Full text
Abstract:
Introduction Diffuse large B cell lymphoma (DLBCL) is the most common lymphoid malignancy among older patients (pts), and about 25% of new diagnoses involve population aged > 80y.o. Most clinical trials (CTs) exclude the very older (Kanapuru et al, 2017). Rituximab + miniCHOP is considered gold-standard for untreated DLBCL aged >80 y.o with an overall survival (OS) of ~60% at 2y and improving outcomes for this frail population is challenging. Synthetic control arms (SCA) may engender more innovative randomized trials, by allowing indirect comparisons with enhanced statistical con
APA, Harvard, Vancouver, ISO, and other styles
36

Kelly, Jennifer L., Gilles Salles, Bryan H. Goldman, et al. "Low Serum Vitamin D Levels Are Associated with Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and Lysa Studies." Blood 120, no. 21 (2012): 2712. http://dx.doi.org/10.1182/blood.v120.21.2712.2712.

Full text
Abstract:
Abstract Abstract 2712 Introduction: While follicular lymphoma (FL) prognosis is known to be influenced by clinical characteristics and age, investigation of modifiable factors in the modern treatment era with prognostic significance has been limited. Binding of the active vitamin D metabolite to the nuclear vitamin D receptor results in autocrine and paracrine effects possibly relevant to both cancer prevention and prognosis, including regulation of cell proliferation, induction of apoptosis and differentiation, and immune modulation. Recent literature reports a potential association between
APA, Harvard, Vancouver, ISO, and other styles
37

Marouf, Amira, Cedric Rossi, Tesla Murairi, et al. "Outcomes of Patients Treated with Consolidative Brentuximab Vedotin after Transplant for Hodgkin Lymphoma at High Risk of Progression or Relapse: An Innovative Comparative Analysis Based on Propensity Score Weighting from Patients Included in 4 Lysa-Cohorts." Blood 144, Supplement 1 (2024): 4424. https://doi.org/10.1182/blood-2024-209608.

Full text
Abstract:
Introduction: The landmark AETHERA study showed the safety and efficacy of Brentuximab Vedotin (BV) use as maintenance in high-risk relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL). Several studies, including AMAHRELIS, confirmed its effectiveness in a real-life setting. However, the field of HL management is evolving, including practice changes in the second-line treatment that might impact patient outcomes after autologous stem cell transplant outcomes (ASCT). In that setting, it is unclear whether the indication for consolidative BV can still rely on the current criteria defini
APA, Harvard, Vancouver, ISO, and other styles
38

Willaume, A., L. Chartier, R. Ricci, et al. "Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype in the RT3 and REMARC trials—A LYSA retrospective analysis." Hematological Oncology 41, S2 (2023): 346–47. http://dx.doi.org/10.1002/hon.3164_248.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Copie Bergman, Christiane, Elodie Bohers, Peggy Dartigues-Cuillères, et al. "Real Time Pathological and Molecular Characterization of Aggressive B-Cell Lymphomas Based on a National Network. a Lysa Project." Blood 136, Supplement 1 (2020): 22–23. http://dx.doi.org/10.1182/blood-2020-141953.

Full text
Abstract:
Introduction Aggressive B-cell lymphomas are heterogeneous in their clinical course and biological characteristics. They include diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS), high grade-B-cell lymphoma with double/triple-hit or NOS (HGBL), primary mediastinal B-cell lymphoma (PMBL). In order to better differentiate these entities, the WHO classification recommends using immunohistochemistry (IHC), FISH, targeted sequencing and gene expression profiles (GEP). However, these techniques are most often performed retrospectively in clinical trials, which is not representative o
APA, Harvard, Vancouver, ISO, and other styles
40

Ysebaert, Loic, Roch Houot, Olivier Casasnovas, et al. "Real-Word Experience of CAR T-Cells in Patients with Relapsed/Refractory Follicular Lymphoma : A Descart Registry Analysis from the Lysa." Blood 142, Supplement 1 (2023): 296. http://dx.doi.org/10.1182/blood-2023-184653.

Full text
Abstract:
Background: Anti-CD19 CAR T-cells have revolutionized the treatment of aggressive B-cell non-Hodgkin lymphomas (NHL) by demonstrating durable responses. Although follow-up remain short, axicabtagene ciloleucel (axi-cel, ZUMA-5) and tisagenlecleucel (tisa-cel, ELARA) demonstrated promising complete response rates (CRR) of 86% and 69%, respectively, in phase II trials including relapsed or refractory (R/R) follicular lymphoma (FL).. Tisa-cel and axi-cel are now approved after at least 2 lines of systemic therapy by the FDA. Few real-word evidence (RWE) data have been reported so far. Methods: Pa
APA, Harvard, Vancouver, ISO, and other styles
41

Johnston, Katie E., Kate O’Connell, Naoimh Flynn, et al. "Abstract PS15-04: Impact of a dietitian and nurse-led survivorship clinic utilizing ePRO collection on body composition and muscle strength in early-stage breast cancer: Results from the Linking You to Support and Advice (LYSA) Randomized Control Trial." Clinical Cancer Research 31, no. 12_Supplement (2025): PS15–04—PS15–04. https://doi.org/10.1158/1557-3265.sabcs24-ps15-04.

Full text
Abstract:
Abstract Background: Breast cancer history and adjuvant endocrine therapy use are associated with unfavorable body composition alterations, including increased body weight and adipose tissue mass and decreased muscle mass and strength. Qualitative research highlights that breast cancer survivors are unlikely to receive optimal support to manage these alterations. We evaluated the impact of a dietetic intervention utilizing electronic patient reported outcomes (ePROs) on body composition in a randomized control survivorship trial. Methods: LYSA (n=200) was a multisite randomized control trial w
APA, Harvard, Vancouver, ISO, and other styles
42

Thieblemont, Catherine, Bettina Altmann, Olivier Casasnovas, et al. "CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL." Journal of Clinical Oncology 39, no. 15_suppl (2021): 7543. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.7543.

Full text
Abstract:
7543 Background: Central nervous system (CNS) relapse occurs in 2-6% of DLBCL patients (pts) increasing to 10% or more in high-risk groups. Intrathecal (IT) or intravenous high-dose methotrexate (HD MTX) have limited if any prophylactic impact on CNS relapse. To address the role of systemic first-line therapy in pts tolerating intensified strategies (R-ACVBP, R-(Mega)CHOEP, R-CHO(E)P), we compared CNS relapses occurring in a large cohort of pts ≤60 years. Methods: We conducted a retrospective analysis including previously untreated pts with DLBCL by central review, age 18-60 years, from multic
APA, Harvard, Vancouver, ISO, and other styles
43

Rossi, Cédric, Julia Gilhodes, Marie Maerevoet, et al. "Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers." Blood 130, Suppl_1 (2017): 652. http://dx.doi.org/10.1182/blood.v130.suppl_1.652.652.

Full text
Abstract:
Abstract Introduction: Hodgkin lymphoma (HL) pts who relapse after high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV) therapy have a poor outcome. For these relapsed and refractory (R/R) HL pts, anti-PD-1 therapy gives a high rate of objective responses. However, the rate of complete response (CR) remains modest and in the updated results of anti-PD-1 therapy clinical trials, about 50% of pts are still without progressive disease after one year of treatment. As anti-PD-1 therapy modifies the anticancer immune response, we hypothesize that anti-
APA, Harvard, Vancouver, ISO, and other styles
44

Canioni, Danielle, Pauline Brice, Serge Bologna, et al. "Prognostic Value of Immunohistochemical Markers in Stage III/IV Classical Hodgkin Lymphoma Treated Frontline in the Lysa EORTC 20012 Randomized Protocol." Blood 132, Supplement 1 (2018): 4132. http://dx.doi.org/10.1182/blood-2018-99-118039.

Full text
Abstract:
Abstract Introduction: Clinical evolution of classical Hodgkin lymphoma (cHL) cannot be always predicted by clinical, biological or radiological parameters. Given the high treatment related morbidity of clinical trials it should be interesting to get other prognostic markers to predict cHL patients evolution. Some immunohistochemical (IHC) markers have been already published as prognostic in cHL but they are still matter to debate. We have tested 13 IHC markers in the LYSA H3/4 trial of cHL which compares patients with stage III to IV cHL in a phase III who were assigned to either doxorubicin,
APA, Harvard, Vancouver, ISO, and other styles
45

Clerico, Michele, Axel André, Pierre Sesques, et al. "CAR T-Cells Treatment for Relapsed/Refractory B-Cell Lymphoma Is Effective and Safe in People Living with HIV (PLWH): A Lysa Study from the Descar-T Registry." Blood 144, Supplement 1 (2024): 3124. https://doi.org/10.1182/blood-2024-205388.

Full text
Abstract:
Background Despite antiretroviral therapy (ART), people living with HIV (PLWH) have an increased risk for occurrence of lymphomas, and B-cell lymphomas remain the leading cause of AIDS-related deaths in the Western world. Moreover, given the improved life expectancy due to the use of combined ART, age-related lymphoid neoplasms are expected to be more frequently diagnosed in PLWH in the future. Although anti-CD19 chimeric antigen receptor T-cells (CAR T) represent a major advance in the treatment of relapsed/refractory (R/R) B-cell lymphomas, PLWH have been excluded from clinical trials. Here,
APA, Harvard, Vancouver, ISO, and other styles
46

Delarue, Richard, Pier Luigi Zinzani, Mark S. Hertzberg, et al. "ROCHOP study: A phase III randomized study of CHOP compared to romidepsin-CHOP in untreated peripheral T-cell lymphoma." Journal of Clinical Oncology 31, no. 15_suppl (2013): TPS8616. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.tps8616.

Full text
Abstract:
TPS8616 Background: Peripheral T-cell lymphomas (PTCL) account for 10-15% of lymphomas. They share an aggressive clinical behaviour and a poor prognosis when treated by CHOP-like regimen which is nevertheless consider as a standard because others regimens failed to demonstrate survival advantage. Romidepsin is a histone deacetylase inhibitor with promising results in PTCL. First trials showed a response rate of 38% in heavily pre-treated PTCL patients. These results were confirmed with 15% of patients reaching a CR/CRu, 89% of them without disease progression at 13 months. Adverse events inclu
APA, Harvard, Vancouver, ISO, and other styles
47

Sarkozy, Clementine, Loïc Chartier, Vincent Ribrag, et al. "Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials." Blood 142, Supplement 1 (2023): 299. http://dx.doi.org/10.1182/blood-2023-173615.

Full text
Abstract:
Background The prognosis of mantle cell lymphoma (MCL) has largely improved in the past decade; however, the disease is characterized by a heterogeneous clinical course. Several retrospective studies identified early progression of disease (i.e. within two years, POD24) as a potential overall survival (OS) surrogate, but this has not been validated in cohorts of patients prospectively included in clinical trials in rituximab maintenance era. Methods We performed a pooled analysis of French patients with MCL included in six randomized clinical trials (EU-MCL younger NCT00209222, LyMA NCT0092141
APA, Harvard, Vancouver, ISO, and other styles
48

Michot, Jean-Marie, Cédric Portugues, Lucie Oberic, et al. "Long-Term Follow-up Study of Patients Aged 80 Years or Older Treated By Attenuated Chemotherapy Mini-CHOP Plus Anti-CD20 for DLBCL, Update of the LNH03-7B and LNH09-7B Lysa Trials." Blood 144, Supplement 1 (2024): 4467. https://doi.org/10.1182/blood-2024-202588.

Full text
Abstract:
Background. The aging of the population and the increased risk of lymphoma with age are two concordant factors to consider an increased frequency of B lymphomas in the coming years. Continuous effort are required to optimize tolerability and efficacy of treatments for the frail elderly population over 80 years of age not eligible for standard chemotherapy doses regimens. LNH03-7B (NCT01087424; Peyrade F et al, Lancet Oncol 2011) and LNH09-7B (NCT01195714; Peyrade F et al, Lancet Haematol 2017) clinical trials studies conducted in patients (pts) over 80 years of age, demonstrated attenuated dos
APA, Harvard, Vancouver, ISO, and other styles
49

Cabannes-Hamy, Aurelie, Frederic Peyrade, Fabrice Jardin, et al. "Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies." Blood 128, no. 22 (2016): 927. http://dx.doi.org/10.1182/blood.v128.22.927.927.

Full text
Abstract:
Abstract Background. The prevalence of diffuse large B-cell lymphoma (DLBCL) in patients aged over 80 years is reported to have tripled compared to patients in their sixties. Treating very elderly patients is particularly challenging given the likelihood of comorbidities and concerns over risks of toxicity. One of the most devastating and rapidly fatal complications in DLBCL is central nervous system (CNS) relapse. Most studies reporting incidence and risk factors of CNS relapse concern DLBCL patients under the age of 80 years, and little is known about CNS recurrence in the very elderly, aged
APA, Harvard, Vancouver, ISO, and other styles
50

Herbaux, Charles, Caroline Bret, Roberta Di Blasi, et al. "Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study from the Descar-T Registry and Lysa Group." Blood 138, Supplement 1 (2021): 743. http://dx.doi.org/10.1182/blood-2021-148626.

Full text
Abstract:
Abstract Introduction The French health agency granted access to KTE-X19 in its early access program (French ATUs) for patients with relapsed or refractory (R/R) mantle-cell lymphoma (MCL) who failed after at least one line of chemoimmunotherapy and Bruton's tyrosine kinase (BTK) inhibitor. DESCAR-T is the French national registry for all patients treated with CAR-T cells (commercial or early access program). DESCAR-T designed and sponsored by LYSA/LYSARC aims to collect "real-life" data about CAR-T cell eligible patients in all hematological malignancies. We report the first results of "real-
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography